Figure 3.
Co-targeting AURKA and MDM2 blocks melanoma growth in vivo. (A) Mice bearing SK-Mel5 xenografts received daily treatments with (−)-Nutlin-3 (200mg/kg), MLN8237 (30mg/kg), combination of both or vehicle control. Tumor volume changes over time are shown. (B) Western Blot analysis of tumors (T) described in A. Expression was normalized to β-actin and average fold changes ± SD in different treatment groups over the placebo group were plotted (right panels). (C) Representative results of SA-βGal, Ki-67 and AIF staining in tumors described in A. Percentages of AIF and Ki-67-positive cells were quantified using ImageJ software; SA-βGal staining was scored by pathologist in a blind fashion. Five random fields of 2–3 tumors were evaluated in each treatment group and average values per tumor ± SD are shown. V- vehicle, N- (−)-Nutlin-3, M- MLN8237, MN- combined MLN8237 and (−)-Nutlin-3 treatment.